03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
07:00 , May 12, 2014 |  BC Week In Review  |  Company News

Nordion, Sterigenics deal

Sterigenics raised its acquisition price for Nordion to $12.25 per share from $11.75 in response to an unsolicited competing offer from an undisclosed third party. The third party submitted a bid of $12.25 on April...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Clinical News

TheraSphere regulatory update

The U.K.'s NICE issued guidance recommending the use of selective internal radiation therapy (SIRT), which includes BTG's TheraSphere, for patients with primary hepatocellular carcinoma or those with intrahepatic cholangiocarcinoma. TheraSphere - yttrium-90 glass microspheres used...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

BTG, Nordion deal

BTG completed its acquisition of Therasphere liver cancer therapy from Nordion for $200 million. The yttrium-90 glass microspheres used for localized radioembolization therapy is approved in Europe and Canada to treat hepatic neoplasia (see BioCentury,...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

BTG, Ekos Corp., Nordion deal

BTG announced a pair of deals last week with Nordion and Ekos. BTG will acquire TheraSphere liver cancer therapy from Nordion for $200 million. The product, which had revenues of $48 million for the fiscal...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biogen Idec Inc. (NASDAQ:BIIB) was up $8.39 to $235.24 last week after submitting a BLA to FDA for Plegridy peginterferon beta-1a ( BIIB017 ) to treat relapsing forms of multiple sclerosis (MS). The...
00:34 , May 24, 2013 |  BC Extra  |  Company News

BTG announces fundraising, deals

BTG plc (LSE:BTG) raised L106.3 million ($161.5 million) through the sale of 32.3 million shares at 330p in a placing on Thursday and also announced a pair of deals. BTG will acquire TheraSphere liver cancer...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Company News

Nordion cancer, supply/service news

Nordion restructured to form two business units, effective Nov. 1. Nordion said the move is designed to take into account the unique product life cycles and customer needs in each of the businesses. A targeted...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Nordion cancer news

Nordion said the company is conducting an internal investigation of potential improper payments and financial irregularities related to a foreign supplier. Nordion discovered the irregularities through the company's own internal review as part of its...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Nordion sales and marketing update

Nordion launched a custom dose feature in Europe and Canada for its TheraSphere microsphere therapy to treat liver cancer. Nordion said the custom doses provide treatment flexibility for physicians and reduce administration time, product waste...